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Abstract
Autism spectrum disorders (ASDs) represent a group of childhood neurodevelopmental and
neuropsychiatric disorders characterized by deficits in verbal communication, impairment of social
interaction, and restricted and repetitive patterns of interests and behaviour. To identify common
genetic risk factors underlying ASDs, here we present the results of genome-wide association studies
on a cohort of 780 families (3,101 subjects) with affected children, and a second cohort of 1,204
affected subjects and 6,491 control subjects, all of whom were of European ancestry. Six single
nucleotide polymorphisms between cadherin 10 (CDH10) and cadherin 9 (CDH9)—two genes
encoding neuronal cell-adhesion molecules—revealed strong association signals, with the most
significant SNP being rs4307059 (P = 3.4 × 10−8, odds ratio = 1.19). These signals were replicated
in two independent cohorts, with combined P values ranging from 7.4 × 10−8 to 2.1 × 10−10. Our
results implicate neuronal cell-adhesion molecules in the pathogenesis of ASDs, and represent, to
our knowledge, the first demonstration of genome-wide significant association of common variants
with susceptibility to ASDs.
ASDs encompass a range of clinically defined conditions, including autism and pervasive
developmental disorder not otherwise specified, which are more common and severe, as well
as Asperger's syndrome, which appears less frequently and is milder1. ASDs are about four
times more common in boys than girls, and at present around 1 in 150 children in the United
States have a diagnosis of an ASD2. Several sources of evidence suggest that strong genetic
components are involved in susceptibility to ASDs: there are much higher concordance rates
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of ASDs in monozygotic twins (92%) than dizygotic twins (10%)3, and recent estimate of the
sibling recurrence risk ratio (λs) is 22 for autism4. Despite being highly heritable, ASDs show
heterogeneous clinical symptoms and genetic architecture, which have hindered the
identification of common genetic susceptibility factors5. Although previous linkage studies,
candidate gene association studies and cytogenetic studies have implicated several
chromosomal regions for the presence of autism susceptibility loci6-9, they have failed to
consistently identify and replicate common genetic variants that increase the risk of ASDs.
Besides well-known genetic conditions reported in ASDs, recent studies have identified a
growing number of distinct and individually rare genetic causes, suggesting that the genetic
architecture of ASDs may have a significant contribution from heterogeneous rare variants.
For example, rare de novo copy number variants have been implicated in 7% of families with
ASDs, but only in 1% of control families10. In addition, 16p11.2 microdeletions and
microduplications have been found in approximately 1% of autism cases11,12. Several hundred
rare structural variations have also been catalogued in families with ASDs13. Although these
reported variants indicate a role for rare genomic variation in a proportion of families, no
common variants have been previously associated with ASDs in genome-wide studies. The
latter is consistent with reports from previous genome-wide association studies of other
neuropsychiatric disorders, including bipolar disorder14,15, schizophrenia16 and attention
deficit/hyperactivity disorder16, all of which have failed to identify common susceptibility loci
with genome-wide significance, when individual data sets with small sample sizes were
analysed. However, recent meta-analysis reported evidence for common variants in both
schizophrenia17 and bipolar disorder18, suggesting that the search for common genetic
variation that confer susceptibility to ASDs may benefit from the combined analysis of several
studies.
Genome-wide association studies on ASDs
To identify common genetic risk factors for ASDs, we carried out a genome-wide association
study on 943 ASDs families (4,444 subjects) from the Autism Genetic Resource Exchange
(AGRE cohort, Table 1)19. The subjects with ASDs in the AGRE cohort were diagnosed using
both the Autism Diagnostic Interview-Revised (ADI-R)20 and Autism Diagnostic Observation
Schedule (ADOS)21 diagnostic tools, which are the gold standard diagnostic tools for
individuals with ASDs. All subjects were genotyped using the Illumina HumanHap550
BeadChip with over 550,000 single nucleotide polymorphism (SNP) markers. We applied
stringent quality control criteria (Supplementary Methods), including call rates, Mendelian
inconsistencies and genetically inferred ancestry, to identify a set of 3,101 subjects of European
ancestry in 780 AGRE families for association tests. We performed analysis with the Pedigree
Disequilibrium Test (PDT)22 for autosomes, and with X-APL23 for the X chromosome, using
genotypes from 486,864 markers. The complete sets of SNP genotype data and signal intensity
data were released to the academic research community in April 2008 (http://www.agre.org).
We did not observe genome-wide significant association (P < 5 × 10−8) to ASDs in the AGRE
cohort, but we proposed that meaningful associations were contained within the lowest P
values. To boost power for identifying these associations, we examined an Autism Case-
Control cohort (ACC cohort, Table 1), comprising 1,453 subjects with ASDs from several US
sites, and 7,070 control subjects without ASDs from the Children's Hospital of Philadelphia,
who were also genotyped on the same platform. The subjects with ASDs in this cohort were
diagnosed using the ADI and ADOS tools. After conducting thorough quality control measures
on the geno-types, association analyses were conducted on 1,204 subjects with ASDs and 6,491
control subjects of inferred European ancestry. We did not detect genome-wide significant
association (P < 5 × 10−8) to ASDs in the ACC cohort either. Therefore, we subsequently
performed a combined analysis of these two independent data sets using recommended meta-
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analysis approaches24. From examining autosomes and the X chromosome, one SNP located
on 5p14.1 reached genome-wide significance (rs4307059, P = 3.4 × 10−8), and five further
SNPs at the same locus had Pvalues below 1 × 10−4 (Table 2 and Fig. 1a). Several other loci
contain SNPs with suggestive association signals (Table 3), such as 13q33.3 (near MYO16
(myosin XVI)), 14q21.1 (between FBXO33 (F-box protein 33) and LRFN5 (leucine rich repeat
and fibronectin type III domain containing 5)) and Xp22.32 (between PRKX (protein kinase,
X-linked) and NLGN4X (neuroligin 4, X-linked)). We also analysed ten markers on the Y
chromosome in the ACC cohort, with the most significant SNP being rs2032597 (P = 1.1 ×
10−4) located within USP9Y (ubiquitin specific protease 9, Y-linked) (Supplementary Table
1). Furthermore, we have analysed 15 markers in pseudoautosomal regions of sex
chromosomes in the two discovery cohorts, but no markers showed evidence of association
(Supplementary Table 2).
To identify other variants that associate with ASDs but were not captured by the SNP
genotyping array, we analysed the discovery cohorts using whole-genome imputed genotypes
on autosomes generated by the MACH software (Supplementary Methods). The most
significant association signals were still those in the 5p14.1 region. However, several other
genomic loci, such as 10q21.3 (within CTNNA3 (catenin, alpha 3)) and 16p13.2 (between
A2BP1 (ataxin 2-binding protein 1) and C16orf68 (chromosome 16 open reading frame 68)),
contain imputed SNPs with suggestive association signals (Table 3). Follow-up studies with
larger sample sizes are required to determine whether these represent genuine ASD
susceptibility loci.
Replication of the association signals
To replicate our genome-wide significant association signals at the 5p14.1 locus, we examined
the association statistics for these markers in a third independently generated and analysed
cohort, including 1,390 subjects from 447 autism families genotyped with ~1 million markers
on the Illumina HumanHap1M BeadChip (CAP cohort, Table 1). The association signals for
all the aforementioned SNPs were replicated in this cohort with the same direction of
association, with Pvalues ranging from 0.01 to 2.8 × 10−5 (Table 2). To seek further evidence
of replication, we examined association statistics from a fourth independent cohort of 108 ASD
cases and 540 genetically matched control subjects, genotyped on the Illumina HumanCNV370
BeadChip, an array with over 300,000 SNP markers (CART cohort, Table 1). Because
rs7704909 and rs10038113 were not present in this array platform, we analysed association on
imputed genotypes. Most of the SNPs were replicated (P < 0.05) in the CART cohort with the
same direction of association (Table 2). Combined analysis on all four data sets indicates that
all six SNPs are associated with ASDs, with Pvalues ranging from 7.4 × 10−8 to 2.1 × 10−10
(Table 2 and Supplementary Table 3). Taken together, several sources of converging evidence
firmly established that common genetic variants on 5p14.1 confer susceptibility to ASDs.
Genomic features of the 5p14.1 region
Closer examination of the 5p14.1 region indicated that all genotyped and imputed SNPs with
P values below 1 × 10−7 reside within the same ~100 kilobase (kb) linkage disequilibrium
block, suggesting that these SNPs are tagging the same variants (Supplementary Figs 1 and 2).
The linkage disequilibrium block is located within a 2.2-megabase (Mb) intergenic region
between CDH10 (cadherin 10) and CDH9 (cadherin 9) (Fig. 1b, c). Both CDH10 and CDH9
encode type II classical cadherins from the cadherin superfamily, which represent
transmembrane proteins that mediate calcium-dependent cell-cell adhesion. To search for other
types of variants, including copy number variations (CNVs), in the intergenic region, we used
the PennCNV software25 on the signal intensity data and identified five CNV loci
(Supplementary Fig. 3). All of these CNVs are present in control subjects in our study, and
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three of the five CNVs are also reported in the Database for Genomic Variants that annotates
healthy individuals (Supplementary Fig. 4), suggesting that CNVs in the region are unlikely
to be causal variants for ASDs.
We next focused on the ~100 kb linkage disequilibrium block containing the most significant
SNPs, and determined whether other transcripts or functional elements are located in the block.
By examining the UCSC Genome Browser annotations26, we did not identify predicted genes,
predicted transcription start sites, spliced human expressed sequence tag (EST) sequences,
known microRNA genes or predicted microRNA targets that overlap with the linkage
disequilibrium block (Supplementary Fig. 5). However, we note that the linkage disequilibrium
block contains several highly conserved genomic elements, including a 849-base pair (bp)
element that ranks as the top 0.026% most-conserved elements in the entire human genome
(log odds (LOD) score 5 3,480 by PhastCons27, Fig. 1b). Consistent with previous reports that
large stable gene deserts typically contain regulatory elements for genes involved in
development or transcription28, we hypothesized that these tagging SNPs were capturing the
association of functional variants that regulate the expression and action of either CDH10 or
CDH9.
Expression of CDH10 and CDH9 in brain
Because CDH10 and CDH9 are expressed at low levels in non-neural tissues (Supplementary
Figs 6 and 7), we evaluated their messenger RNA distribution in human fetal brain by in situ
hybridization. Multiple sagittally sectioned human fetal brains, each between 19 and 20 weeks
gestation, were hybridized with riboprobes against CDH10 or CDH9. Results for CDH9,
showing uniformly low levels of expression at the time points evaluated, were largely
uninformative. In contrast, a marked pattern of enrichment for CDH10 was observed in the
frontal cortex (Fig. 2a)—a region known to be important in ASDs. The expression pattern was
similar to that for CNTNAP2 (contactin-associated protein-like 2)29, a molecule now well-
established to be involved in the ASDs1. These results are consistent with previous work
showing high levels of CDH10 in the human fetal brain30 and a prominent enrichment of
Cdh10 mRNA in the anterior cortical plate of the developing mouse brain31.
To examine whether the SNP genotypes associate with gene expression for CDH10 and
CDH9, we next examined the SNPExpress database32 that profiles gene expression in 93
human cortical brain tissues from genotyped subjects. However, none of the SNPs in Table 2
was associated with expression levels for either CDH9 (P = 0.92 for rs4307059) or CDH10
(P = 0.86 for rs4307059) (Fig. 2b). Although the small sample size may not have sufficient
power to detect subtle effect sizes, it is also possible that the causal variants regulate gene
expression only in the developing brain, or that the causal variants target an unidentified
functional element, similar to the variants reported in the intergenic region on 8q24, which
have been implicated in various cancers33,34.
Pathway analysis of cell-adhesion genes
Recent genetic studies have identified several neuronal cell-adhesion genes, including
NRXN1 (neurexin 1)35,36, CNTNAP2 (refs 37-39) and PCDH10 (protocadherin 10)40, as
potentially disrupted in rare ASD cases. Cadherins represent a large group of transmembrane
proteins that are involved in cell adhesion and the generation of synaptic complexity in the
developing brain41. In light of the information described earlier, we note that several other
cadherin genes were also tagged by the top 1,000 most significant SNPs of the combined
discovery cohorts (Supplementary Table 4). In addition, SNPs surrounding several prominent
ASD candidate loci1, including CACNA1C (L type voltage-gated calcium channel),
CNTNAP2, GRIK2 (glutamate receptor, ionotropic, kainate 2), NRXN1 and NLGN4X, also
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show suggestive evidence of association (Supplementary Table 5). These sources of evidence
indicate a potential role for cell-adhesion molecules in the pathogenesis of ASDs.
To examine if cell-adhesion molecules, as a gene family, associate with ASDs, we applied two
pathway-based association approaches on the genotype data (Supplementary Methods). First,
we assign each SNP to the overlapping or the closest gene, summarize the significance of each
gene using the Simes-adjusted P value42 from its SNPs, and then test whether the distribution
of P values differ between a group of genes and all other genes using a nonparametric rank
sum test. Using the combined P values from the two discovery cohorts, we found that a group
of 25 related cadherin genes show more significant association with ASDs than all other genes
(P = 0.02), whereas a stronger enrichment signal (P = 0.004) was obtained when the 25 cadherin
genes were combined with eight neurexin family genes (NRXN1 to NRXN3, CNTNAP1 to
CNTNAP5). Second, we analysed the ACC cohort using a formal pathway-association method
for case-control data sets43. This method examines whether statistics for a group of genes have
modest yet consistent deviation from what is expected by chance, through shuffling case/
control labels many times, each time recalculating P values for all SNPs. We confirmed that
the set of cadherin genes is associated with ASDs (permutation P = 0.02), whereas the combined
cadherin/neurexin genes show more significant association (permutation P = 0.002). Therefore,
our pathway analysis suggests that neuronal cell-adhesion molecules may be collectively
associated with ASDs.
Discussion
Besides recent genetic findings supporting the role of neuronal cell-adhesion molecules in the
pathogenesis of autism, an increasing number of functional neuroimaging studies have
suggested the presence of cortical underconnectivity in subjects with ASDs44,45. Furthermore,
neuroanatomy studies have implicated abnormal brain development of the frontal lobes in
autism46,47. The genetic findings, when coupled with anatomical and functional imaging
studies, convergently indicate that ASDs may result from structural and functional
disconnection of brain regions that are involved in higher-order associations48-50, suggesting
that ASDs may represent a neuronal disconnection syndrome.
In the current study, we have completed a genetic analysis in a large number of ASD cases and
families, with a combined sample set of more than 10,000 subjects of European ancestry. We
have identified and replicated common genetic variants on 5p14.1 that are associated with
susceptibility to ASDs. Besides the potential roles of the nearby CDH10 and CDH9 genes,
pathway-based association analysis lend further support to neuronal cell-adhesion molecules
in conferring susceptibility to ASDs, suggesting that specific genetic variants in this gene class
may be involved in shaping the physical structure and functional connectivity of the brain, that
leads to the clinical manifestations of ASDs. Apart from highlighting the genetic complexity
of ASDs and the need for large sample sizes in unveiling their genetic causes, our study
represents a successful application of the genome-wide association approach in identifying
common susceptibility alleles, as part of a larger effort to interrogate the complex genetic
architecture of ASDs. Because the genetic aetiologies of ASDs may be linked to the
neurobiological components that build and modify connectivity of the brain, by
comprehensively identifying the relevant genes, genomic variants and genetic pathways, more
focused analysis on gene expression, as well as structural and functional imaging, can be
performed on subjects carrying specific genetic defects. Together with studies addressing
epigenetic modifications and comprehensive analysis of environmental risk factors, these
pieces of information can be better integrated to improve our understanding of the molecular
basis of ASDs, and foster the development of early preventive and corrective strategies.
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All genome-wide SNP genotyping for the discovery cohorts was performed using the Illumina
HumanHap550 BeadChip at the Center for Applied Genomics at the Children's Hospital of
Philadelphia. For family-based cohorts, the association tests for markers in autosomes and
pseudoautosomal region of sex chromosomes were performed by PDT, whereas tests for
markers in the X chromosome were performed by X-APL. For case-control cohorts, the
association tests were performed by PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/).
Pathway association analysis was performed by GenGen
(http://www.openbioinformatics.org/gengen/), using the genotype data. The whole-genome
genotype imputation was performed by MACH
(http://www.sph.umich.edu/csg/abecasis/MaCH/) on the autosomal markers, on the basis of
phased haplotypes (release 22) for the HapMap CEU population
(http://ftp.hapmap.org/phasing/2007-08_rel22/). We removed all markers with MACH Rsq
measure of less than 0.3, and zeroed out imputed genotypes with a posterior probability of less
than 0.9. The case-control association tests for imputed genotypes were performed by
SNPTEST (http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html), which can
handle genotype imputation uncertainty. CNV calls were generated by PennCNV
(http://www. openbioinformatics.org/penncnv/) on genotyping signal intensity data. For CNV
validation by multiplex ligation-dependent probe amplification (MLPA), we used the
Universal Probe Library system from Roche, and all reactions were performed in triplicate
with an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). For CNV
validation by quantitative PCR (qPCR), TaqMan probes were custom-designed using Primer
Express 3.0 (Applied Biosystems). For in situ hybridization, multiple sagittally sectioned
human fetal brains were obtained from the Developmental Brain and Tissue Bank at the
University of Maryland. Riboprobes against CDH9 or CDH10 were used for hybridization.
The SNPExpress database and software
(http://people. genome.duke.edu/~dg48/SNPExpress/) were used to examine the genotype-
expression relationships.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We gratefully thank all the children with ASDs and their families at the participating study sites who were enrolled
in this study and all the control subjects who donated blood samples to Children's Hospital of Philadelphia (CHOP)
for genetic research purposes. We also acknowledge the resources provided by the AGRE Consortium (D. H.
Geschwind, M. Bucan, W. T. Brown, J. D. Buxbaum, R. M. Cantor, J. N. Constantino, T. C. Gilliam, C. M. Lajonchere,
D. H. Ledbetter, C. Lese-Martin, J. Miller, S. F. Nelson, G. D. Schellenberg, C. A. Samango-Sprouse, S. Spence, M.
State, R. E. Tanzi) and the participating families. AGRE is a program of Autism Speaks and is at present supported,
in part, by grant 1U24MH081810 from the National Institute of Mental Health to C. M. Lajonchere (PI), and formerly
by grant MH64547 to D. H. Geschwind (PI). We thank the technical staff at the Center for Applied Genomics at CHOP
for producing the genotypes used for analyses, and the nursing, medical assistant and medical staff for their help with
recruitment of patient and control subjects for the study. We thank R. Liu and I. Lindquist for helping with CNV
validation. We thank D. J. Hedges, H. N. Cukier, J. L. McCauley, G. W. Beecham, H. H. Wright, R. K. Abramson,
E. R. Martin and J. P. Hussman for their comments, advice and statistical support, and the laboratory core and the
autism clinical personnel at the Miami Institute for Human Genomics and the autism clinical staff at the Vanderbilt
Center for Human Genetics Research. A subset of the CAP participants was ascertained while M.A.P.-V. was a faculty
member at Duke University. We thank the National Institutes of Health (NIH)-funded Developmental Brain and Tissue
Bank at University of Maryland for access to the fetal brain tissues used in these studies (National Institute of Child
Health and Human Development Contract no. NO1-HD-4-3368 and NO1-HD-4-3383). All genotyping of the AGRE
and ACC cohort was supported by an Institutional Development Award to the Center for Applied Genomics (H.H.)
at the Children's Hospital of Philadelphia. The study was supported in part by a Research Award from the Margaret
Q. Landenberger Foundation (H.H.), a Research Development Award from the Cotswold Foundation (H.H. and
S.F.A.G), UL1-RR024134-03 (H.H.), an Alavi-Dabiri fellowship from Mental Retardation and Developmental
Wang et al. Page 7













Disability Research Center at CHOP (K.W.), the Beatrice and Stanley A. Seaver Foundation (J.D.B.), the Department
of Veterans Affairs (G.D.S.), NIH grants HD055782-01 (J.Munson, A.E., O.K., G.D. and G.D.S.), MH0666730
(J.D.B.), MH061009 and NS049261 (J.S.S.), HD055751 (E.H.C.), MH69359, M01-RR00064 and the Utah Autism
Foundation (H.C., J.Miller and W.M.M.), MH64547, MH081754 (D.H.G.), HD055784 (D.H.G. and M.S.), NS26630,
NS36768, MH080647 and a gift from the Hussman Foundation (M.A.P.-V.), the Autism Genome Project Consortium
(B.S.A., J.P., C.W.B., D.H.G., T.H.W., W.M.M., H.C., J.I.N., J.S.S., E.H.C., J.Munson, A.E., O.K., J.D.B., B.D. and
G.D.S.) funded by Autism Speaks, the Medical Research Council (UK) and the Health Research Board (Ireland). We
also acknowledge the partial support to CAP cohort from the Autism Genome Project.
References
1. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology.
Nature Rev. Genet 2008;9:341–355. [PubMed: 18414403]
2. Autism and Developmental Disabilities Monitoring Network. 2007. 〈
http://www.cdc.gov/mmwr/pdf/ss/ss5601.pdf 〉
3. Bailey A, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol.
Med 1995;25:63–77. [PubMed: 7792363]
4. Lauritsen MB, Pedersen CB, Mortensen PB. Effects of familial risk factors and place of birth on the
risk of autism: a nationwide register-based study. J. Child Psychol. Psychiatry 2005;46:963–971.
[PubMed: 16108999]
5. Sykes NH, Lamb JA. Autism: the quest for the genes. Expert Rev. Mol. Med 2007;9:1–15. [PubMed:
17764594]
6. Gupta AR, State MW. Recent advances in the genetics of autism. Biol. Psychiatry 2007;61:429–437.
[PubMed: 16996486]
7. Freitag CM. The genetics of autistic disorders and its clinical relevance: a review of the literature. Mol.
Psychiatry 2007;12:2–22. [PubMed: 17033636]
8. Veenstra-VanderWeele J, Cook EH Jr. Molecular genetics of autism spectrum disorder. Mol.
Psychiatry 2004;9:819–832. [PubMed: 15197396]
9. Vorstman JAS, et al. Identification of novel autism candidate regions through analysis of reported
cytogenetic abnormalities associated with autism. Mol. Psychiatry 2006;11:18–28.
10. Sebat J, et al. Strong association of de novo copy number mutations with autism. Science
2007;316:445–449. [PubMed: 17363630]
11. Weiss LA, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N.
Engl. J. Med 2008;358:667–675. [PubMed: 18184952]
12. Kumar RA, et al. Recurrent 16p11.2 microdeletions in autism. Hum. Mol. Genet 2008;17:628–638.
[PubMed: 18156158]
13. Marshall CR, et al. Structural variation of chromosomes in autism spectrum disorder. Am. J. Hum.
Genet 2008;82:477–488. [PubMed: 18252227]
14. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of
seven common diseases and 3,000 shared controls. Nature 2007;447:661–678. [PubMed: 17554300]
15. Sklar P, et al. Whole-genome association study of bipolar disorder. Mol. Psychiatry 2008;13:558–
569. [PubMed: 18317468]
16. Alkelai A, et al. The XVth world congress of psychiatric genetics, October 7–11, 2007: rapporteur
summaries of oral presentations. Am. J. Med. Genet. B. Neuropsychiatr. Genet 2008;174B:233–277.
[PubMed: 18297693]
17. O'Donovan MC, et al. Identification of loci associated with schizophrenia by genome-wide association
and follow-up. Nature Genet 2008;40:1053–1055. [PubMed: 18677311]
18. Ferreira MA, et al. Collaborative genome-wide association analysis supports a role for ANK3 and
CACNA1C in bipolar disorder. Nature Genet 2008;40:1056–1058. [PubMed: 18711365]
19. Geschwind DH, et al. The autism genetic resource exchange: a resource for the study of autism and
related neuropsychiatric conditions. Am. J. Hum. Genet 2001;69:463–466. [PubMed: 11452364]
20. Lord C, Rutter M, Le Couteur A. Autism diagnostic interview-revised: a revised version of a
diagnostic interview for caregivers of individuals with possible pervasive developmental disorders.
J. Autism Dev. Disord 1994;24:659–685. [PubMed: 7814313]
Wang et al. Page 8













21. Lord C, et al. The autism diagnostic observation schedule-generic: a standard measure of social and
communication deficits associated with the spectrum of autism. J. Autism Dev. Disord 2000;30:205–
223. [PubMed: 11055457]
22. Martin ER, Monks SA, Warren LL, Kaplan NL. A test for linkage and association in general pedigrees:
the pedigree disequilibrium test. Am. J. Hum. Genet 2000;67:146–154. [PubMed: 10825280]
23. Chung RH, Morris RW, Zhang L, Li YJ, Martin ER. X-APL: an improved family-based test of
association in the presence of linkage for the X chromosome. Am. J. Hum. Genet 2007;80:59–68.
[PubMed: 17160894]
24. de Bakker PI, et al. Practical aspects of imputation-driven meta-analysis of genome-wide association
studies. Hum. Mol. Genet 2008;17:R122–R128. [PubMed: 18852200]
25. Wang K, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy
number variation detection in whole-genome SNP genotyping data. Genome Res 2007;17:1665–
1674. [PubMed: 17921354]
26. Kuhn RM, et al. The UCSC genome browser database: update 2009. Nucleic Acids Res
2009;37:D755–D761. [PubMed: 18996895]
27. Siepel A, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes.
Genome Res 2005;15:1034–1050. [PubMed: 16024819]
28. Ovcharenko I, et al. Evolution and functional classification of vertebrate gene deserts. Genome Res
2005;15:137–145. [PubMed: 15590943]
29. Abrahams BS, et al. Genome-wide analyses of human perisylvian cerebral cortical patterning. Proc.
Natl Acad. Sci. USA 2007;104:17849–17854. [PubMed: 17978184]
30. Kools P, Vanhalst K, Van den Eynde E, van Roy F. The human cadherin-10 gene: complete coding
sequence, predominant expression in the brain, and mapping on chromosome 5p13–14. FEBS Lett
1999;452:328–334. [PubMed: 10386616]
31. Visel A, Thaller C, Eichele G. GenePaint.org: an atlas of gene expression patterns in the mouse
embryo. Nucleic Acids Res 2004;32:D552–D556. [PubMed: 14681479]
32. Heinzen EL, et al. Tissue-specific genetic control of splicing: implications for the study of complex
traits. PLoS Biol 2008;6:e1000001.
33. Witte JS. Multiple prostate cancer risk variants on 8q24. Nature Genet 2007;39:579–580. [PubMed:
17460686]
34. Ghoussaini M, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J.
Natl. Cancer Inst 2008;100:962–966. [PubMed: 18577746]
35. Kim HG, et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am. J. Hum. Genet
2008;82:199–207. [PubMed: 18179900]
36. Szatmari P, et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements.
Nature Genet 2007;39:319–328. [PubMed: 17322880]
37. Arking DE, et al. A common genetic variant in the neurexin superfamily member CNTNAP2 increases
familial risk of autism. Am. J. Hum. Genet 2008;82:160–164. [PubMed: 18179894]
38. Alarcon M, et al. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-
susceptibility gene. Am. J. Hum. Genet 2008;82:150–159. [PubMed: 18179893]
39. Bakkaloglu B, et al. Molecular cytogenetic analysis and resequencing of contactin associated protein-
like 2 in autism spectrum disorders. Am. J. Hum. Genet 2008;82:165–173. [PubMed: 18179895]
40. Morrow EM, et al. Identifying autism loci and genes by tracing recent shared ancestry. Science
2008;321:218–223. [PubMed: 18621663]
41. Redies C. Cadherins in the central nervous system. Prog. Neurobiol 2000;61:611–648. [PubMed:
10775799]
42. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika
1986;73:751–754.
43. Wang K, Li M, Bucan M. Pathway-based approaches for analysis of genomewide association studies.
Am. J. Hum. Genet 2007;81:1278–1283.
44. Just MA, Cherkassky VL, Keller TA, Minshew NJ. Cortical activation and synchronization during
sentence comprehension in high-functioning autism: evidence of underconnectivity. Brain
2004;127:1811–1821. [PubMed: 15215213]
Wang et al. Page 9













45. Koshino H, et al. fMRI investigation of working memory for faces in autism: visual coding and
underconnectivity with frontal areas. Cereb. Cortex 2008;18:289–300. [PubMed: 17517680]
46. Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. Trends Neurosci 2008;31:137–
145. [PubMed: 18258309]
47. Courchesne E, Pierce K. Why the frontal cortex in autism might be talking only to itself: local over-
connectivity but long-distance disconnection. Curr. Opin. Neurobiol 2005;15:225–230. [PubMed:
15831407]
48. Hughes JR. Autism: the first firm finding = underconnectivity? Epilepsy Behav 2007;11:20–24.
[PubMed: 17531541]
49. Frith C. Is autism a disconnection disorder? Lancet Neurol 2004;3:577. [PubMed: 15380151]
50. Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr.
Opin. Neurobiol 2007;17:103–111. [PubMed: 17275283]
51. Ma DQ, et al. A genome-wide association study of autism reveals a common novel risk locus at
5p14.1. Ann. Hum. Genet. doi:10.1111/j.1469-1809.2008.00523.x (in the press).
Wang et al. Page 10













Figure 1. Genome-wide association results for the 5p14.1 region
a, A Manhattan plot showing the −log10(P values) of SNPs from the combined association
analysis of the AGRE and ACC cohorts. b, The 5p14.1 genomic region is displayed in UCSC
Genome Browser, with conserved genomic elements in the PhastCons track. c, Both genotyped
(diamonds) and imputed (grey circles) SNPs are plotted with their combined P values in all
four cohorts. Genotyped SNPs were coloured on the basis of their correlation with rs4307059
(red: r2 ≥ 0.5; yellow: 0.2 ≤ r2 < 0.5; white: r2 < 0.2). Estimated recombination rates from
HapMap data are plotted to reflect the local linkage disequilibrium structure.
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Figure 2. Examination of brain expression for CDH10 and CDH9
a, The in situ hybridization of CDH10 in human fetal brain sectioned in the sagittal plane.
Medial and lateral sections from a representative sample are shown above corresponding
cresyl-violet-stained marker slides. Orbitofrontal cortex (OFC) and frontal cortex (FC) are
highlighted, with marked expression enrichment. b, The SNP genotypes of rs4307059 are not
associated with CDH9 or CDH10 transcript levels in 93 cortical brain tissues.
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